You are here

  • Home
  • Archive
  • Volume 65, Issue 10
  • JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia
  1. Achille Pich1,
  2. Ludovica Riera1,2,
  3. Eloise Beggiato3,
  4. Barbara Nicolino3,
  5. Laura Godio1,
  6. Paola Campisi1,
  7. Francesca Sismondi2,
  8. Paola Francia di Celle2
  1. 1Department of Biomedical Sciences and Human Oncology, Section of Pathology, University of Turin, Turin, Italy
  2. 2Center for Experimental Research and Medical Studies (CERMS), University of Turin, Turin, Italy
  3. 3Haemostasis and Thrombosis Unit, Department of Haematology, San Giovanni Hospital, Turin, Italy
  1. Correspondence to Professor Achille Pich, Department of Biomedical Sciences and Human Oncology, Section of Pathology, University of Turin, Via Santena 7, I-10126 Torino, Italy; achille.pich{at}unito.it

https://doi.org/10.1136/jclinpath-2012-200804

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Essential thrombocythaemia (ET) is a chronic myeloproliferative neoplasm (MPN) that primarily involves the megakaryocytic lineage.1 The JAK2V617F mutation has been detected in 50–60% of ETs, and homozygous mutation in only 5%.2

    JAK2V617F mutation has been associated with a polycythaemia vera (PV)-like phenotype3 and increased risk of thrombosis,4 especially in homozygous patients.5 Increasing mutant allele load was correlated with older age, splenomegaly, microvessel symptoms and higher frequency of arterial thrombosis at diagnosis.2

    Little is known on the association between JAK2V617F mutation and histological changes in bone marrow biopsy (BMB) of ET patients.

    One hundred and three consecutive patients with newly diagnosed ET, admitted to the Division of Haematology, S. Giovanni Hospital and University of Turin, Italy, from 2006 to 2010 were included in the study. Diagnosis of ET was performed according to WHO criteria.1 A general informed consent was obtained according to the local ethical committee guidelines. There were 56 women and 47 men; the mean age was 59.1 years (range, 25–86). Splenomegaly was detected in 38 patients (36.9%). Venous or arterial thrombosis (confirmed by ultrasound examination or CT scan and D-dimer assessment) were found in 21% and 7% of patients, respectively. …

    View Full Text

    Footnotes

    • Funding This work was supported by grants from the Italian Ministero dell'Università e Ricerca Scientifica e Tecnologica (MURST).

    • Competing interests None.

    • Ethics approval Ethics approval was provided by Ethics Committee of A.S.O San Giovanni Battista—A.S.O. C.T.O./C.R.F./ Maria Adelaide of Turin.

    • Provenance and peer review Not commissioned; externally peer reviewed.